Want to see APLM full AI Analyst Report?
APLM Stock Chart & Stats
$26.20
$0.44(2.42%)
At close: 4:00 PM EDT
$26.20
$0.44(2.42%)
Day’s Range― - ―
52-Week Range$10.01 - $36.53
Previous CloseN/A
Volume30.00
Average Volume (3M)8.59K
Market Cap
$64.27M
Enterprise Value$5.88M
Total Cash (Recent Filing)$3.28M
Total Debt (Recent Filing)$643.00K
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.57
Shares Outstanding2,914,965
10 Day Avg. Volume5,264
30 Day Avg. Volume8,593
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-8.48
Price to Sales (P/S)3.18
P/FCF Ratio-2.61
Enterprise Value/Market Cap0.09
Enterprise Value/Revenue0.69
Enterprise Value/Gross Profit0.69
Enterprise Value/Ebitda-0.63
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-122
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ExpansionThe sharp increase in reported revenue indicates materially improved commercial or partnering traction compared with the prior year. If this activity can be repeated, it may provide a stronger base for financing development, validating the pipeline and supporting future collaboration opportunities.
Low Reported DebtReported debt remains modest in absolute terms, limiting direct interest and repayment pressure relative to a heavily leveraged biotechnology company. This gives management more flexibility to pursue development or partnerships without the additional burden of substantial debt service, despite broader funding challenges.
Reduced Cash BurnThe year-over-year reduction in cash burn suggests improved cash discipline or operating performance compared with 2024. Although cash generation remains negative, sustaining this improvement would extend available funding and reduce the pace at which external capital is needed to support research and development.
Bears Say
Persistent LossesApollomics remains deeply unprofitable despite the revenue increase, showing that current activity is not yet covering operating and development costs. Continued losses can constrain reinvestment, increase reliance on financing or partners, and make progress toward a self-sustaining commercial model more difficult.
Negative EquityThe shift from positive to negative equity represents a significant weakening in financial resilience. For a loss-making clinical-stage biotech, this reduces balance-sheet flexibility, may complicate access to capital, and increases the importance of successful partnerships, financing transactions or clinical progress.
Ongoing External Funding NeedPersistent negative free cash flow means operations and research spending are consuming cash rather than funding themselves. Unless cash generation improves materially, the company will remain dependent on external financing, licensing proceeds or other capital sources to maintain development activities over time.
Apollomics News
APLM FAQ
What was Apollomics’s price range in the past 12 months?
Apollomics lowest stock price was $10.01 and its highest was $36.52 in the past 12 months.
What is Apollomics’s market cap?
Apollomics’s market cap is $64.27M.
When is Apollomics’s upcoming earnings report date?
Apollomics’s upcoming earnings report date is Apr 01, 2027 which is in 163 days.
How were Apollomics’s earnings last quarter?
Apollomics released its earnings results on Apr 27, 2026. The company reported $3.795 earnings per share for the quarter.
Is Apollomics overvalued?
According to Wall Street analysts Apollomics’s price is currently Overvalued.
Does Apollomics pay dividends?
Apollomics does not currently pay dividends.
What is Apollomics’s EPS estimate?
Apollomics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Apollomics have?
Apollomics has 2,914,965 shares outstanding.
What happened to Apollomics’s price movement after its last earnings report?
Apollomics reported an EPS of $3.795 in its last earnings report. Following the earnings report the stock price went up 0.342%.
Which hedge fund is a major shareholder of Apollomics?
Currently, no hedge funds are holding shares in APLM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apollomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-39.84%
12-Months-Change
Fundamentals
Return on Equity
288.40%
Trailing 12-Months
Asset Growth
―
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Apollomics
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Technical Analysis
Vyome Holdings
―
Collplant Holdings
―
Lunai Bioworks
―
Exicure
―
CytoMed Therapeutics Limited
―
Ownership Overview
56.98% Insiders
0.02% Mutual Funds
― Other Institutional Investors
42.99% Public Companies and
Individual Investors